Notably, the majority of reported TRMA patients have ancestral origins in the Middle East, South Asia, and the Northern Mediterranean region, with more than 60% being homozygous for SLC19A2 due to consanguinity among their parents.6 Here, SLC19A2 is linked to thiamine-responsive megaloblastic anemia syndrome.